Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma
Status:
Unknown status
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
Currently, there is no standard treatment for primary pulmonary lymphoepithelioid carcinoma.
Apatinib is a new kind of Vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine
kinase inhibitors (TKIs). A disease-control rate of 75% was found in lung cancer patients in
a phase II clinical study. Therefore, researchers hope to explore the efficacy and safety of
apatinib in the treatment of primary pulmonary lymphoepithelioid carcinoma.